國家衛生研究院 NHRI:Item 3990099045/5719

NHRI > National Institute of Infectious Diseases and Vaccinology > Shih-Jen Liu > Periodical Articles > Item 3990099045/5719

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/5719

Title:	T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer
Authors:	Chan, PKS;Liu, SJ;Cheung, JLK;Cheung, TH;Yeo, W;Chong, P;Man, S
Contributors:	Division of Vaccine Research and Development
Abstract:	The E6 and E7 proteins encoded by human papillomaviruses (HPV) are prime targets for therapeutic vaccine development. Ninety-five women with HPV 52 infection (33 transient infections, 17 cervical intraepithelial neoplasia grade II, 15 cervical intraepithelial neoplasia grade III, and 30 invasive cervical cancers) were examined for T-cell responses using interferon-gamma enzyme-linked immunospot (IFN-gamma ELISPOT) assay. Of the 29 peptides (13 L1, 10 E6, and 6 E7) screened positive by an in vitro peptide-binding assay, 14 were positive by the IFN-gamma ELISPOT assay. Positive epitopes for HLAA11 were located at amino acid positions 103-111, 332-340, 342-350, and 373-381 of the L1 protein; and at 27-35 and 86-94 of the E6 protein; and at 1-9 and 27-35 of the E7 protein. A24-specific epitopes included 60-68 and 98-106 of the L1 protein, 42-50 and 59-67 of the E6 protein, and 24-32 of the E7 protein. Only one epitope (99-107) of the E6 protein showed positive responses for HLA A2 subjects. Overall, T-cell responses against L1 were observed mainly in subjects who had cleared infection; whereas responses against E6 and E7 were confined mainly to subjects who had developed cervical neoplasia. The proportion of subjects showing detectable T-cell responses was low across all grades of cervical neoplasia suggesting that immune evasion mechanisms had set on early in the course of disease progression. This study provides the first set of T-cell epitopes mapped for HPV 52, which can be considered for further evaluation as targets for immunotherapy. J. Med. Virol. 83:1023-1030, 2011.
Date:	2011-06
Relation:	Journal of Medical Virology. 2011 Jun;83(6):1023-1030.
Link to:	http://dx.doi.org/10.1002/jmv.21889
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0146-6615&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000289960500014
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=79954578372
Appears in Collections:	[Shih-Jen Liu] Periodical Articles [Pele Choi-Sing Chong] Periodical Articles

Files in This Item:

File	Description	Size	Format
ISI000289960500014.pdf		98Kb	Adobe PDF	496	View/Open

Loading...